



## Pharmacy Drug Policy & Procedure

<b>Policy Name:</b>	<b>Rezdiffra (resmetirom)</b>	<b>Policy#:</b>	<b>3374P</b>
---------------------	-------------------------------	-----------------	--------------

### Purpose of the Policy

The purpose of this policy is to define coverage criteria for Rezdiffra (resmetirom).

### Statement of the Policy

Health Alliance Medical Plans will approve the use of Rezdiffra (resmetirom) under the specialty pharmacy benefit if the following criteria are met.

### Criteria

#### 1. Coverage Criteria

- 1.1 Diagnosis of noncirrhotic nonalcoholic steatohepatitis (liver disease) (NASH/MASH)
  - Diagnosis confirmed by one of the following: liver biopsy, elastography (MRE or VCTE), magnetic resonance imaging (MRI), serum or imaging biomarker (Fibroscan, NFS, ELF)
- 1.2 Evidence of moderate to advanced liver fibrosis as evidenced by stages F2 to F3 fibrosis
- 1.3 Age 18 years or older
- 1.4 Prescribed by or in consultation with a hepatologist (liver doctor)
- 1.5 Evidence of additional conditions such as prediabetes or type 2 diabetes, obesity, hypertension, etc
- 1.6 Rezdiffra will be used in addition to diet and exercise

#### 2. Exclusion Criteria

- 2.1 Evidence of decompensated cirrhosis
- 2.2 F1 or F4 fibrosis
- 2.3 Evidence of significant alcohol consumption (defined as  $\geq 20$ g/day for females or  $\geq 30$ g/day for males)

#### 3. Managed Dose Limit

- 3.1 #30 tablets per 30 days

#### 4. Approval Period

- 4.1 Initial: 12 months
- 4.2 Reauthorization: 12 months with documented clinical benefit from therapy

### CPT Codes

--	--

### HCPCS Codes

--	--

### References

1. Rezdiffra (resmetirom) [prescribing information]. West Conshohocken, PA: Madrigal Pharmaceuticals Inc; March 2024.

2. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 8;390(6):497-509.
3. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology 81(1):p 312-320, January 2025.

**Created Date:** 04/02/25

**Effective Date:** 04/02/25

**Posted to Website:** 04/02/25

**Revision Date:**

#### DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.